Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,982
archived clinical trials in
Endocrine

An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly
Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients
Status: Enrolling
Updated:  8/10/2016
University of Michigan Health System StudyCoordinatorCSOM230B2201E1
mi
from
Ann Arbor, MI
An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly
Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients
Status: Enrolling
Updated: 8/10/2016
University of Michigan Health System StudyCoordinatorCSOM230B2201E1
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly
Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients
Status: Enrolling
Updated:  8/10/2016
NYU / VA Medical Center
mi
from
New York, NY
An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly
Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients
Status: Enrolling
Updated: 8/10/2016
NYU / VA Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly
Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients
Status: Enrolling
Updated:  8/10/2016
Novartis Investigative Site
mi
from
Woolloongabba,
An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly
Extension to a Multi-center, Randomized, Crossover, Open Label, Dose Finding Study to Compare the Safety, Efficacy, and Pharmacokinetics/Pharmacodynamics (PK/PD) Relationship of Multiple Doses of Pasireotide (SOM230) (200, 400, and 600 μg Bid) and Doses of Open Label Sandostatin® (SMS) (100 μg Tid) in Acromegalic Patients
Status: Enrolling
Updated: 8/10/2016
Novartis Investigative Site
mi
from
Woolloongabba,
Click here to add this to my saved trials
Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery
A Prospective, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Pilot Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery
Status: Enrolling
Updated:  8/11/2016
William Beaumont Health Center
mi
from
Royal Oak, MI
Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery
A Prospective, Randomized, Double-Blind, Double-Dummy,Placebo-Controlled, Parallel-Group, Pilot Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery
Status: Enrolling
Updated: 8/11/2016
William Beaumont Health Center
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Intravenous Exenatide (Byetta) During Surgery
Intravenous Exenatide (Byetta) for the Treatment of Perioperative Hyperglycemia: Rollover Phase I/II Trial
Status: Enrolling
Updated:  8/17/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Intravenous Exenatide (Byetta) During Surgery
Intravenous Exenatide (Byetta) for the Treatment of Perioperative Hyperglycemia: Rollover Phase I/II Trial
Status: Enrolling
Updated: 8/17/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Intravenous Immunoglobulin for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)
A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)
Status: Enrolling
Updated:  8/31/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Intravenous Immunoglobulin for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)
A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)
Status: Enrolling
Updated: 8/31/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Popular Diets Study
Popular Diets, Metabolism, and CVD Risk
Status: Enrolling
Updated:  11/22/2016
Children's Hospital Boston
mi
from
Boston, MA
Popular Diets Study
Popular Diets, Metabolism, and CVD Risk
Status: Enrolling
Updated: 11/22/2016
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Fatty Acid Metabolism and Insulin Sensitivity After Exercise in Obesity
Fatty Acid Metabolism and Insulin Sensitivity After Exercise in Obesity
Status: Enrolling
Updated:  11/22/2016
Michigan Clincal Research Unit
mi
from
Ann Arbor, MI
Fatty Acid Metabolism and Insulin Sensitivity After Exercise in Obesity
Fatty Acid Metabolism and Insulin Sensitivity After Exercise in Obesity
Status: Enrolling
Updated: 11/22/2016
Michigan Clincal Research Unit
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
mi
from
Roseville, CA
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
mi
from
Roseville, CA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
mi
from
Cooper City, FL
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
mi
from
Cooper City, FL
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
mi
from
Miami Springs, FL
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
mi
from
Miami Springs, FL
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
mi
from
Bronx, NY
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
mi
from
Bronx, NY
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
mi
from
Columbus, OH
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
mi
from
Bethlehem, PA
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
mi
from
Chattanooga, TN
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
mi
from
Greenville, TX
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
mi
from
Greenville, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
mi
from
Houston, TX
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated:  11/28/2016
Questcor Investigational Site
mi
from
San Antonio, TX
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria.
Status: Enrolling
Updated: 11/28/2016
Questcor Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
Status: Enrolling
Updated:  11/30/2016
Massachusetts General Hospital
mi
from
Boston, MA
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
Status: Enrolling
Updated: 11/30/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
Status: Enrolling
Updated:  11/30/2016
Cleveland Clinic Endocrinology, Diabetes and Metabolism
mi
from
Cleveland, OH
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
Status: Enrolling
Updated: 11/30/2016
Cleveland Clinic Endocrinology, Diabetes and Metabolism
mi
from
Cleveland, OH
Click here to add this to my saved trials
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
Status: Enrolling
Updated:  11/30/2016
Allegheny Endocrinology Associates
mi
from
Pittsburgh, PA
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
Status: Enrolling
Updated: 11/30/2016
Allegheny Endocrinology Associates
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
Status: Enrolling
Updated:  11/30/2016
Oregon Health and Sciences University
mi
from
Portland, OR
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis
Status: Enrolling
Updated: 11/30/2016
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Testosterone and Alendronate in Hypogonadal Men
Testosterone and Alendronate in Hypogonadal Men
Status: Enrolling
Updated:  11/30/2016
Massachusetts General Hospital
mi
from
Boston, MA
Testosterone and Alendronate in Hypogonadal Men
Testosterone and Alendronate in Hypogonadal Men
Status: Enrolling
Updated: 11/30/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Glycogen Storage Disease Expression in Carriers
Characterizing Expression of Glycogen Storage Disease in Heterozygous Carriers
Status: Enrolling
Updated:  12/1/2016
University of Florida
mi
from
Gainesville, FL
Study of Glycogen Storage Disease Expression in Carriers
Characterizing Expression of Glycogen Storage Disease in Heterozygous Carriers
Status: Enrolling
Updated: 12/1/2016
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome
Role of Cardiac CT in Risk Factor Control in Asymptomatic Patients With Diabetes
Status: Enrolling
Updated:  12/7/2016
University of California, Irvine Medical Center
mi
from
Orange, CA
Cardiac CT's Role in Asymptomatic Patients With Diabetes and Metabolic Syndrome
Role of Cardiac CT in Risk Factor Control in Asymptomatic Patients With Diabetes
Status: Enrolling
Updated: 12/7/2016
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Los Angeles, CA
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Stanford, CA
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Stanford, CA
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
New Orleans, LA
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Ann Arbor, MI
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Chapel Hill, NC
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Cleveland, OH
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Columbus, OH
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Philadelphia, PA
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated:  12/8/2016
GSK Investigational Site
mi
from
Edmonton,
A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)
Status: Enrolling
Updated: 12/8/2016
GSK Investigational Site
mi
from
Edmonton,
Click here to add this to my saved trials
Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS
Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS
Status: Enrolling
Updated:  12/13/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS
Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS
Status: Enrolling
Updated: 12/13/2016
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Mechanisms of Reduced Ramipril on the Onset of Type 2 Diabetes Mellitis
Status: Enrolling
Updated:  12/20/2016
University of Maryland, Baltimore
mi
from
Baltimore, MD
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Mechanisms of Reduced Ramipril on the Onset of Type 2 Diabetes Mellitis
Status: Enrolling
Updated: 12/20/2016
University of Maryland, Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
Status: Enrolling
Updated:  1/4/2017
Novo Nordisk Investigational Site
mi
from
Princeton, NJ
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
Status: Enrolling
Updated: 1/4/2017
Novo Nordisk Investigational Site
mi
from
Princeton, NJ
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Birmingham, AL
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Mobile, AL
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Phoenix, AZ
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Fullerton, CA
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Inglewood, CA
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Inglewood, CA
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Los Angeles, CA
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Mission Viejo, CA
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Oakland, CA
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Oakland, CA
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Redondo Beach, CA
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Redondo Beach, CA
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Colorado Springs, CO
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Hollywood, FL
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Hollywood, FL
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Miami, FL
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated:  1/16/2017
GSK Investigational Site
mi
from
Pembroke Pines, FL
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG MR) and Metoprolol Succinate Extended Release (TOPROL-XL) on the Reduction of Microalbuminuria in Patients With Hypertension and Microalbuminuria
Status: Enrolling
Updated: 1/16/2017
GSK Investigational Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials